As a part of the COST Action PARENCHIMA, Antaros Medical’s Imaging Director Iris Friedli has contributed to several chapters in the recently published book “Preclinical MRI of the Kidney”.
PARENCHIMA is a renal imaging initiative aiming to fill the gap of non-invasive and sensitive biomarkers for Chronic Kidney Disease (CKD), a disease affecting >10% of the world’s population. Magnetic Resonance Imaging (MRI) biomarkers show a strong potential to help fill this gap and support the development of effective treatments for CKD.